Humira, a biologic medication used to treat autoimmune conditions like psoriasis and rheumatoid arthritis, is the most popular biologic medication in the world. Following the expiration of patent protection for Humira in some regions, biosimilars-which are highly similar copies of biologic medications in terms of safety, efficacy, and quality-have hit the market. These biosimilars encourage competition and may result in price reductions. They help lower costs and improve patient access to essential pharmaceuticals by offering more economical treatment options.
Market Dynamics
Patent expiration, cost savings, increasing prevalence of autoimmune diseases, favorable regulatory environment are major factors expected to drive growth of the global cerebral angiography market during the forecast period.
For instance, the market for multiple Humira biosimilars has been approved and introduced in Europe, which has been in the forefront of the acceptance of biosimilars. Due to the region's existing legal framework and policies supporting biosimilar adoption, there will likely be more market competition and potential cost reductions.
However, complex regulatory processes, intellectual property and patent litigation, and physician and patient awareness are expected to hamper growth of the global cerebral angiography market over the forecast period.
Key features of the study:
- This report provides in-depth analysis of the global humira biosimilar market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global humira biosimilar market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Amneal Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Viatris Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global humira biosimilar market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global humira biosimilar market
Detailed Segmentation:
- Global Humira Biosimilar Market, By Product Type:
- Biosimilar Humira (Adalimumab)
- Interchangeable Biosimilar Humira
- Global Humira Biosimilar Market, By Indication:
- Rheumatoid Arthritis
- Psoriasis
- Crohn's Disease
- Ulcerative Colitis
- Ankylosing Spondylitis
- Juvenile Idiopathic Arthritis
- Other Autoimmune Conditions
- Global Humira Biosimilar Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Humira Biosimilar Market, By Patient Age:
- Adult Patients
- Pediatric Patients
- Global Humira Biosimilar Market, By Application:
- Rheumatology
- Dermatology
- Gastroenterology
- Other Therapeutic Areas
- Global Humira Biosimilar Market, By Administration:
- Subcutaneous (SC) Injection
- Intravenous (IV) Infusion
- Global Humira Biosimilar Market, By Dosage Strength:
- 40 mg/0.8 mL
- Other dosage strengths
- Global Humira Biosimilar Market, By End User:
- Hospitals
- Specialty Clinics
- Others
- Global Humira Biosimilar Market, By Packaging Type:
- Pre-filled Syringes
- Autoinjectors
- Vials
- Global Humira Biosimilar Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
- Company Profiles
- Amgen Inc.
- Samsung Bioepis Co., Ltd.
- Sandoz International GmbH (Novartis AG)
- Mylan N.V.
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Fresenius Kabi AG
- Coherus BioSciences, Inc.
- Biogen Inc.
- AbbVie Inc.
- Celltrion Inc.
- Amneal Pharmaceuticals, Inc.
- Lupin Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Viatris Inc.